iOmx Therapeutics AG (iOmx), a biopharmaceutical company developing cancer therapeutics based on novel immune checkpoint targets, announced today that its Chief Executive Officer Apollon Papadimitriou, Ph.D., will present at Biotech Showcase 2020, to be held January 13-15 at the Hilton San Francisco Union Square in San Francisco.
| MARTINSRIED, Germany and MUNICH, Dec. 16, 2019 /PRNewswire/ -- iOmx Therapeutics AG (iOmx), a biopharmaceutical company developing cancer therapeutics based on novel immune checkpoint targets, announced today that its Chief Executive Officer Apollon Papadimitriou, Ph.D., will present at Biotech Showcase 2020, to be held January 13-15 at the Hilton San Francisco Union Square in San Francisco. During the presentation, Dr. Papadimitriou will highlight iOmx’ emerging pipeline of next-generation cancer therapeutics targeting novel, proprietary immune checkpoint modulators on tumor cells. The company’s pipeline is highlighted by IMT-18, a first-in-class IGSF11-targeting antibody designed to eliminate tumor-induced immune suppression, and IMT-19, a monoclonal antibody that reshapes the tumor micro-environment. iOmx has also discovered additional immune checkpoint inhibitors, including IMT-07, a small molecule tumor necrosis factor (TNF) sensitizer, that offer optionality including partnership opportunities. Key to iOmx is iOTarg™, the company’s proprietary, high-throughput genetic screening platform. iOTarg systematically screens tumor cells for expression of immune modulating proteins, that, when knocked down, increase T cell immunity against cancer cells. Details of the presentation are as follows:
About iOmx Therapeutics Contact:
SOURCE iOmx Therapeutics AG |
View original content:
